Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

Novo Nordisk A/S understated the impact of lookalike weight-loss injections on its market share before lowering its 2025 ...

Novo Nordisk’s Wegovy faces sharp decline in growth forecasts and share value as competition intensifies and compounded drug ...

UBS downgraded its rating of Novo to "neutral" from "buy" and lowered its 12-month price target to 340 Danish krone from 600 Danish krone. Copenhagen-listed shares in Novo, which have slumped by more ...

Noom introduces affordable options for obesity treatments, including Novo Nordisk's Wegovy and GLP-1Rx programs. Read more ...

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...

Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Novo Nordisk has reaped huge profits from the sales of Wegovy and its sister diabetes medication Ozempic, reporting a total sales growth of 36% and an operating profit growth of 44% in 2023, but ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Shares in Novo Nordisk fell as much as six per cent on Friday to their lowest since August 2021, extending recent losses to ...

The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...